Century Therapeutics Inc. (IPSC)
0.96
0.02 (2.65%)
At close: Jan 15, 2025, 9:56 AM
undefined% (undefined)
| Bid | 0.94 |
| Market Cap | 81.64M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.83 |
| PE Ratio (ttm) | -0.52 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.96 |
| Volume | 28,575 |
| Avg. Volume (20D) | 585,942 |
| Open | 0.95 |
| Previous Close | 0.94 |
| Day's Range | 0.95 - 0.98 |
| 52-Week Range | 0.91 - 5.51 |
| Beta | undefined |
About IPSC
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting C...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 18, 2021
Employees 152
Stock Exchange NASDAQ
Ticker Symbol IPSC
Website https://www.centurytx.com
Analyst Forecast
According to 4 analyst ratings, the average rating for IPSC stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 733.16% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Century Therapeutics Inc. is scheduled to release its earnings on Mar 13, 2025,
before market opens.
Analysts project revenue of $975.00K, reflecting a 263.81% YoY growth and earnings per share of -0.44, making a -32.31% decrease YoY.
Analysts project revenue of $975.00K, reflecting a 263.81% YoY growth and earnings per share of -0.44, making a -32.31% decrease YoY.
